a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period (Randomized Period), followed by an 8-week open-label safety extension period, where all subjects receive KRX-0502 (ferric citrate) (Extension Period). The study will consist of 14 clinic visits over a period of 24 weeks. There will be a screening period of up to 14 days; Approximately 230 subjects will be randomized into the Randomized Period in a 1:1 ratio to receive either KRX-0502 or matching placebo, at baseline
a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period (Randomized Period), followed by an 8-week open-label safety extension period, where all subjects receive KRX-0502 (ferric citrate) (Extension Period).